Illumina, Inc. (ILMN)

Market Cap	21.56B -1.0%
Revenue (ttm)	4.29B -2.3%
Net Income	703.00M
EPS	4.46
Shares Out	152.80M
PE Ratio	31.64
Forward PE	28.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,284,092
Open	142.70
Previous Close	144.81
Day's Range	139.79 - 143.56
52-Week Range	68.70 - 155.53
Beta	1.41
Analysts	Hold
Price Target	125.71 (-10.93%)
Earnings Date	Feb 5, 2026

About ILMN

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 28, 2000
• Employees: 10,370
• Stock Exchange: NASDAQ
• Ticker Symbol: ILMN
• Website: https://www.illumina.com

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Analyst Summary

According to 17 analysts, the average rating for ILMN stock is "Hold." The 12-month stock price target is $125.71, which is a decrease of -10.93% from the latest price.

Price Target

$125.71

(-10.93% downside)

Analyst Consensus: Hold